Literature DB >> 3449388

A preliminary metabolic study of alpidem in rat and man.

P Padovani1, P Guinebault, S Vajta, A Durand, J Allen, J P Thenot, P L Morselli.   

Abstract

The metabolism of alpidem, a new anxiolytic agent in the chemical series of imidazopyridines, was investigated in rat and man. In both species the compound is extensively metabolised by three main routes of biotransformation: aromatic oxidation of the imidazopyridine ring; n-dealkylation; and/or aliphatic oxidation of the substituted amide side chains.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3449388     DOI： 10.1007/BF03189916

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


  1 in total

1.  Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry.

Authors:  B Saletu; J Grünberger; L Linzmayer
Journal:  Int Clin Psychopharmacol       Date:  1986-04       Impact factor: 1.659
  1 in total
  1 in total

1.  Clinical pharmacokinetics and tolerability of alpidem in healthy subjects given increasing single doses.

Authors:  J H Jonkman; G Bianchetti; G Grasmeijer; B Oosterhuis; J F Thiercelin; J P Thénot; P Guillet; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.